MUVON Therapeutics is a Swiss biotechnology start-up with the goal of developing and commercializing an autologous cell therapy for the regeneration of skeletal muscle tissue, focusing initially on the treatment of stress urinary incontinence.

Products, services, technology

The MPC therapy uses the patient’s own muscle precursor cells (MPCs), isolated from a small biopsy and expanded under GMP conditions, to regenerate damaged skeletal muscle tissue and thus increasing the muscles contraction strength.


Weinbergstrasse 35, 8006 Zürich, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland